# Acceleron Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acceleron-pharma

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.acceleronpharma.com
- Total disclosed funding: $144M
- Latest round: Series F (Dec 22, 2011)
- Investors on record: 14

## About

Acceleron Pharma, Inc. focuses on developing innovative therapies for serious diseases, particularly in the areas of rare blood disorders and muscle diseases, utilizing its proprietary protein therapeutic platform.Established in 2003 in Cambridge, US, Acceleron Pharma, Inc. specializes in the development of therapies targeting serious diseases. The company has undergone strategic pivots to enhance its focus on muscle diseases and blood disorders. Acceleron has raised a total of USD 450.00 mn through various funding rounds, with the latest being a Private Placement/Follow on in June 2020. Notably, the company was acquired by Merck & Co., Inc. in September 2021 for USD 11.5 bn in cash, marking a significant transition in its operational strategy.Acceleron Pharma, Inc. is dedicated to the research, development, and commercialization of innovative therapies for rare diseases. The company's product portfolio includes treatments for muscle and blood disorders, with a focus on addressing unmet medical needs in these areas. Their therapeutic offerings aim to improve patient outcomes and expand treatment options for healthcare providers globally.In the most recent financial year 2020, Acceleron Pharma, Inc. reported a revenue of USD 92.52 mn. The company faced an EBITDA of USD -163.46 mn, indicating challenges in profitability as it continues to invest in the development of its product pipeline.Acceleron Pharma, Inc. plans to leverage its recent funding of USD 450.00 mn to launch new therapies targeting muscle and blood disorders. The company aims to expand its market presence, particularly in North America and Europe, by 2023, focusing on increasing access to its innovative treatments. The funding will support ongoing clinical trials and the commercialization of new product offerings, thereby facilitating growth and enhancing patient care.

## Funding rounds

- Series F, Dec 22, 2011, $31M — Advanced Technology Ventures, Flagship Pioneering, OrbiMed Advisors, Polaris Partners, Avalon Ventures, Venrock, Sutter Hill Ventures, Bessemer Venture Partners, QVT Financial, MPM BioImpact, Celgene
- Series E, Jul 21, 2010, $1.9M — Advanced Technology Ventures, Flagship Pioneering, OrbiMed Advisors, Polaris Partners, Venrock
- Series E, Jun 10, 2010, $8.4M — Advanced Technology Ventures, Flagship Pioneering, Polaris Partners, Venrock, Bessemer Venture Partners
- Series D, Dec 3, 2009, $11M — Advanced Technology Ventures, Flagship Pioneering, OrbiMed Advisors, Polaris Partners, Venrock, Bessemer Venture Partners
- Series C, Apr 3, 2008, $5M — Advanced Technology Ventures, Flagship Pioneering, OrbiMed Advisors, Polaris Partners, Venrock
- Series C, Oct 30, 2007, $31M — Advanced Technology Ventures, Flagship Pioneering, OrbiMed Advisors, UBS, Polaris Partners, Venrock, Sutter Hill Ventures, Bessemer Venture Partners, MPM BioImpact, QVT funds
- Series B, Jul 31, 2006, $31M — Advanced Technology Ventures, Flagship Pioneering, OrbiMed Advisors, Pitango, Polaris Partners, Venrock, Sutter Hill Ventures
- Series A, Feb 13, 2004, $25M — Advanced Technology Ventures, Flagship Pioneering, Polaris Partners, Venrock, Sutter Hill Ventures

## Investors

- Advanced Technology Ventures (https://capitalatlas.ai/funds/advanced-technology-ventures) — Series A, Series B, Series C, Series D, Series E, Series F
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series A, Series B, Series C, Series D, Series E, Series F
- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C, Series D, Series E, Series F
- Venrock (https://capitalatlas.ai/funds/venrock) — Series A, Series B, Series C, Series D, Series E, Series F
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series A, Series B, Series C, Series F
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C, Series D, Series E, Series F
- Pitango (https://capitalatlas.ai/funds/pitango) — Series B
- UBS — Series C
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series C, Series D, Series E, Series F
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series C, Series F
- QVT funds — Series C
- Avalon Ventures (https://capitalatlas.ai/funds/avalon-ventures) — Series F
- QVT Financial — Series F
- Celgene — Series F